Format

Send to

Choose Destination
Int J Nanomedicine. 2009;4:299-319. Epub 2009 Dec 29.

Nanomedicine in pulmonary delivery.

Author information

1
University of Kentucky, College of Pharmacy, Division of Pharmaceutical Sciences-Drug Development Division, Lexington, KY 40536, USA. heidi.mansour@uky.edu

Abstract

The lung is an attractive target for drug delivery due to noninvasive administration via inhalation aerosols, avoidance of first-pass metabolism, direct delivery to the site of action for the treatment of respiratory diseases, and the availability of a huge surface area for local drug action and systemic absorption of drug. Colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery offer many advantages such as the potential to achieve relatively uniform distribution of drug dose among the alveoli, achievement of improved solubility of the drug from its own aqueous solubility, a sustained drug release which consequently reduces dosing frequency, improves patient compliance, decreases incidence of side effects, and the potential of drug internalization by cells. This review focuses on the current status and explores the potential of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention to their pharmaceutical aspects. Manufacturing processes, in vitro/in vivo evaluation methods, and regulatory/toxicity issues of nanomedicines in pulmonary delivery are also discussed.

KEYWORDS:

colloidal carriers; dendrimer; liposome; nanocarrier systems; polymeric nanoparticle; pulmonary delivery; solid lipid nanoparticle; submicron emulsion

PMID:
20054434
PMCID:
PMC2802043
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center